Published Date: 13 May 2024
DFS after three years was 87% after six years as opposed to 55% after three, but the toxicity was higher.
Read Full NewsBreast cancer is the most commonly diagnosed form of cancer in the world among women, with more than 2.3 million cases a year, and continues to be one of the main causes of cancer-related mortality. Precisely predicting whether ...
The periodization of exercise training could give people undergoing cancer treatment and those in recovery a tailored pathway to support strength and resilience during the challenging journey of cancer care and rehabilitation.
A new clinical trial led by University of Alberta researchers is exploring whether heavy strength training is a safe and beneficial way to help combat the long-term physical challenges faced by head and neck cancer survivors.
1.
Exercise can counter detrimental effects of cancer treatment, review suggests
2.
Another KRAS Inhibitor Scores an Early Win in Advanced Non-Small Cell Lung Cancer
3.
New research points out a promising strategy for treating metastatic medulloblastoma
4.
On all CAR-T products, the FDA is calling for a new boxed warning.
5.
Congress Ditched Fix to Medicare Doc Pay Cut in Skinny Budget Bill
1.
Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers
2.
Insights into Doxorubicin and Liposomal Doxorubicin in Extra-Abdominal Desmoid-Type Fibromatosis
3.
Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools
4.
What Is May-Hegglin Anomaly? Understanding this Rare Blood Disorder
5.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
2.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
3.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation